U.S. Biomarker Clinical Phase Outsourcing Services Market Size & Outlook
U.S. biomarker clinical phase outsourcing services market, 2018-2030 (US$M)
Related Markets
U.S. biomarker clinical phase outsourcing services market highlights
- The U.S. biomarker clinical phase outsourcing services market generated a revenue of USD 2,813.2 million in 2023 and is expected to reach USD 10,196.7 million by 2030.
- The U.S. market is expected to grow at a CAGR of 20.2% from 2024 to 2030.
- In terms of segment, surrogate endpoints was the largest revenue generating biomarker type in 2023.
- Predictive Biomarkers is the most lucrative biomarker type segment registering the fastest growth during the forecast period.
Biomarker clinical phase outsourcing services market data book summary
| Market revenue in 2023 | USD 2,813.2 million |
| Market revenue in 2030 | USD 10,196.7 million |
| Growth rate | 20.2% (CAGR from 2023 to 2030) |
| Largest segment | Surrogate endpoints |
| Fastest growing segment | Predictive Biomarkers |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers, Surrogate Endpoints |
| Key market players worldwide | Labcorp Holdings Inc, PAREXEL, Icon PLC, Charles River Laboratories International Inc, Proteome Sciences PLC, H U Group Holdings Inc, Wuxi AppTec Co Ltd, NorthEast BioLab, Celerion, GenScript ProBio |
Other key industry trends
- In terms of revenue, U.S. accounted for 38.4% of the global biomarker clinical phase outsourcing services market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. biomarker clinical phase outsourcing services market is projected to lead the regional market in terms of revenue in 2030.
- U.S. is the fastest growing regional market in North America and is projected to reach USD 10,196.7 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Biomarker Clinical Phase Outsourcing Services Market Scope
Biomarker Clinical Phase Outsourcing Services Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
U.S. biomarker clinical phase outsourcing services market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to biomarker clinical phase outsourcing services market will help companies and investors design strategic landscapes.
Surrogate endpoints was the largest segment with a revenue share of 55.74% in 2023. Horizon Databook has segmented the U.S. biomarker clinical phase outsourcing services market based on predictive biomarkers, prognostic biomarkers, safety biomarkers, surrogate endpoints covering the revenue growth of each sub-segment from 2018 to 2030.
Reasons to subscribe to U.S. biomarker clinical phase outsourcing services market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. biomarker clinical phase outsourcing services market databook
-
Our clientele includes a mix of biomarker clinical phase outsourcing services market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. biomarker clinical phase outsourcing services market , including forecasts for subscribers. This country databook contains high-level insights into U.S. biomarker clinical phase outsourcing services market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
U.S. biomarker clinical phase outsourcing services market size, by biomarker type, 2018-2030 (US$M)
U.S. Biomarker Clinical Phase Outsourcing Services Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
